

Coronavirus disease (COVID-19)

Situation Report – 133

Data as received by WHO from national authorities by 10:00 CEST, 01 June 2020

Highlights

WHO has published a [case report form for suspected cases of multisystem inflammatory syndrome \(MIS\) in children and adolescents temporally related to COVID-19](#)

During the last two weeks, [WHO has delivered](#) over 55 tons of health [supplies by road to northeast Syria](#). These shipments contained equipment and medical supplies to treat many diseases, including COVID-19.

[“Clean hands save lives” and “Applaud healthcare workers” campaigns celebrated in North Macedonia](#). Midwives and nurses were honored with applause, as over 500 healthcare professionals were awarded the “Clean hands” certificate of recognition by WHO.

Since the start of the pandemic, there has been an urgent need to accelerate the research and development of COVID-19 candidate vaccines. WHO has been supporting this effort. Currently [over 120 candidate vaccines](#) have been mapped and sites in 40 countries have expressed an interest to join the Vaccine Solidarity Trial. For more on this, see the ‘[Subject in Focus](#)’ below.

Situation in numbers (by WHO Region)

Total (new cases in last 24 hours)

Globally	6 057 853 cases (122 917)	371 166 deaths (4 000)
Africa	104 242 cases (3 632)	2 638 deaths (84)
Americas	2 817 232 cases (73 439)	160 514 deaths (2 812)
Eastern Mediterranean	520 137 cases (15 136)	12 627 deaths (274)
Europe	2 159 791 cases (17 244)	180 594 deaths (509)
South-East Asia	272 512 cases (11 933)	7 743 deaths (312)
Western Pacific	183 198 cases (1 533)	7 037 deaths (9)

Subject in Focus: Accelerating Research for the development of a Vaccine against COVID-19

Since the start of the pandemic, there has been an urgent need to accelerate the research and development of COVID-19 candidate vaccines. Under the umbrella of the Global Research Roadmap, the WHO Working Group for Vaccine Prioritization was constituted under the leadership of the R&D Blueprint team. This working group provides guidance to vaccine developers from a public health perspective and prioritizes vaccine development options vaccine platform approaches and/or candidates to be considered for further development and potentially considered for late-stage evaluation in the context of the global COVID-19 pandemic.


In the past three months, since its creation following the Global Research and Innovation forum hosted by WHO on 11-12 February, important progress has been achieved including:

- **Continuously landscaping and mapping candidate vaccines and their progress across the world.** Currently, over 120 [candidate vaccines](#) have been mapped, raising the question of how to prioritize the ones that will go from early to later development (from phase I to phase 2b/3 clinical trials).
- **Developing specific [criteria](#)** that vaccine scientists, product developers, manufacturers, regulators and funding agencies can use for prioritization.
- **Outlining the desired characteristics for safe and effective vaccines, published in the [WHO Target Product Profiles \(TPP\) for COVID-19 vaccines](#).** The TPP outlines the preferred and minimally acceptable profiles for a human COVID-19 vaccine for long-term protection of persons at high ongoing risk of COVID-19, such as healthcare workers, and for reactive use in outbreak settings with rapid onset of immunity to guide vaccine development.
- **Developing a [core protocol](#) for a globally coordinated randomized controlled clinical trial for vaccines.** Recognizing the critical importance to world health of the rapid availability and deployment of effective vaccines against COVID-19, on 9 April WHO published the core protocol for an international, multi-site, individually randomized controlled clinical trial that will enable the concurrent evaluation of benefits and risks of each promising candidate vaccine within 3–6 months of it being made available for the trial.
- **Launching a [call for expressions](#) of interest from vaccine trial sites around the world using the core protocol, which will include several candidate COVID-19 vaccines that meet WHO prioritization criteria.** This will prepare for the launch of a Solidarity Trial for Vaccines that will build on the platform launched for the Therapeutics Solidarity Trial ([see Situation Report 119](#)) and lessons learned. Currently, over 150 sites in more than 40 countries have expressed an interest in joining a Vaccine Solidarity Trial.
- **Launching a call for interest in engaging on animal studies** for vaccine evaluations with 17 laboratories in 8 countries with animal laboratory facilities.

- **Establishing an Expert Group focusing on COVID-19 viruses, reagents and immune assays.** The goal of the group is to advance the development of COVID-19 medical countermeasures (vaccines and immunotherapeutic). This is being achieved by providing a platform to discuss availability of viruses and key reagents, to share data on immune assays and the potential for cross reactivity of SARS-CoV-2 with other coronaviruses.
- **Establishing an Expert Group focusing on COVID-19 disease modelling and animal models that would replicate human COVID-19 with the goal of accelerating testing of vaccines and therapeutics.** WHO provides a pre-clinical model forum to share information and prevent unnecessary repetition of effort.
- **Coordinating the Human Challenge Studies Working Group,** tasked with consider the feasibility, utility, realistic timelines and approximate costs for establishing a closely monitored experimental challenge model of infection with SARS-CoV-2 (fully virulent or attenuated) in healthy adult volunteers. The Expert Group will also discuss the procedures to be codified and logistical obstacles to be overcome to perform such challenge studies and to propose practical solutions to overcome identified hurdles.


Further information on WHO's work relating to vaccine research can be found on this [webpage](#).

Figure 1. Number of confirmed COVID-19 cases reported in the last seven days by country, territory or area, 26 May to 01 June**



****See [Annex 1](#) for data, table and figure notes.**

Figure 2. Number of confirmed COVID-19 cases, by date of report and WHO region, 30 December 2019 through 01 June 2020**



**See [Annex 1](#) for data, table and figure notes.

Table 1. Countries, territories or areas with reported laboratory-confirmed COVID-19 cases and deaths, by WHO region. Data as of 10 AM CEST, 01 June 2020**

Africa						
South Africa	32 683	1 716	683	40	Community transmission	0
Nigeria	10 162	307	287	14	Community transmission	0
Algeria	9 394	127	653	7	Community transmission	0
Ghana	7 881	113	36	1	Community transmission	0
Cameroon	5 904	245	191	6	Community transmission	0
Guinea	3 771	65	23	0	Community transmission	0
Senegal	3 645	110	42	0	Community transmission	0
Democratic Republic of the Congo	3 048	83	71	3	Community transmission	0
Côte d'Ivoire	2 833	34	33	0	Community transmission	0
Gabon	2 655	42	17	2	Community transmission	0
Kenya	1 962	74	64	1	Community transmission	0
Guinea-Bissau	1 322	66	8	0	Community transmission	0
Mali	1 265	15	77	1	Community transmission	0
Ethiopia	1 172	109	11	3	Clusters of cases	0
Zambia	1 057	0	7	0	Community transmission	4
Equatorial Guinea	1 043	0	12	0	Community transmission	8
Central African Republic	1 011	137	2	1	Clusters of cases	0
South Sudan	994	0	10	0	Clusters of cases	3
Niger	958	2	64	0	Community transmission	0
Burkina Faso	881	28	53	0	Community transmission	0
Sierra Leone	861	9	46	0	Community transmission	0

Chad	778	19	65		Community transmission	0
Madagascar	771	13	6		Clusters of cases	
Congo	604	17	20		Community transmission	0
Mauritania	530		23		Clusters of cases	0
United Republic of Tanzania	509	0	21			24
Uganda	458	12				

Namibia	24	1	0	0	Sporadic cases	0
Seychelles	11	0	0	0	Clusters of cases	55
Lesotho	2	0	0	0	Sporadic cases	9
Territories ⁱⁱ						
Mayotte	1 871	128	23	2	Clusters of cases	0
Réunion	471	0	1	0	Clusters of cases	1
Americas						
United States of America	1 734 040	17 962	102 640	1 073	Community transmission	0
Brazil	498 440	33 274	28 834	956	Community transmission	0
Peru	155 671	7 386	4 371	141	Community transmission	0
Chile	99 688	4 830	1 054	57	Community transmission	0
Canada	90 516	775	7 092	96	Community transmission	0
Mexico	87 512	2 885	9 779	364	Community transmission	0
Ecuador	39 098	527	3 358	24	Community transmission	0
Colombia	28 236	1 548	890	37	Community transmission	0
Dominican Republic	17 285	377	502	4	Community transmission	0
Argentina	16 214	1 512	530	20	Community transmission	0
Panama	13 018	487	330	4	Community transmission	0
Bolivia (Plurinational State of)	9 592	861	310	10	Community transmission	0
Honduras	5 094	208	201	2	Community transmission	0
Guatemala	4 739	132	102	12	Community transmission	0
El Salvador	2 517	122	46	2	Community transmission	0
Cuba	2 045	20	83	0	Clusters of cases	0
Haiti	1 865	281	41	6	Community transmission	0

Venezuela (Bolivarian Republic of)	1 459	89	14	0	Community transmission	0
Costa Rica	1 047	25	10	0	Clusters of cases	0
Paraguay	986	22	11	0	Community transmission	0
Nicaragua	885	0	35	0	Community transmission	3
Uruguay	821	5	22	0	Clusters of cases	0
Jamaica	581	6	9	0	Clusters of cases	0
Guyana	152	2	12	1	Clusters of cases	0
Trinidad and Tobago	117	1	8	0	Sporadic cases	0
Bahamas	101	0	11	0	Clusters of cases	2
Barbados	92	0	7	0	Clusters of cases	7
Saint Vincent and the Grenadines	26	1	0	0	Sporadic cases	0
Antigua and Barbuda	25	0	3	0	Clusters of cases	28
Grenada	23	0	0	0	Clusters of cases	5
Belize	18	0	2	0	Sporadic cases	47
Saint Lucia	18	0	0	0	Sporadic cases	27
Dominica	16	0	0	0	Clusters of cases	51
Saint Kitts and Nevis	15	0	0	0	Sporadic cases	41
Suriname	14	2	1	0	Sporadic cases	0
Territories ⁱⁱ						
Puerto Rico	3 776	58	136	3	Community transmission	0
French Guiana	477	41	1	0	Clusters of cases	0
Martinique	200	0	14	0	Clusters of cases	1
Guadeloupe	162	0	14	0	Clusters of cases	2
Cayman Islands	141	0	1	0	Clusters of cases	1

Bermuda	140	0	9	0	Clusters of cases	2
Aruba	101	0	3	0	Sporadic cases	26
Sint Maarten	78	0	15	0	Sporadic cases	18
United States Virgin Islands	69	0	6	0	Clusters of cases	21
Saint Martin	41					

Bahrain	11 398	605	19	2	Clusters of cases	0
Morocco	7 807	27	205	1	Clusters of cases	0
Iraq	6 439	260	205	10	Clusters of cases	0
Sudan	5 026	226	286	24	Community transmission	0
Djibouti	3 354	160	24	2	Clusters of cases	0
Somalia	1 976	60	78	5	Sporadic cases	0
Lebanon	1 220	29	27	1	Clusters of cases	0
Tunisia	1 077	1	48	0	Community transmission	0
Jordan	739	5	9	0	Clusters of cases	0
Yemen	327	13	81	3	Pending	0
Libya	156	26	5	0	Clusters of cases	0
Syrian Arab Republic	122	0	5	1	Community transmission	3
Territories ⁱⁱ						
occupied Palestinian territory	627	1	5	0	Clusters of cases	0
Europe						
Russian Federation	414 878	9 035	4 855	162	Clusters of cases	0
The United Kingdom	274766	1 936	38 489	113	Community transmission	0
Spain	239 801	201	29 045	2	Community transmission	0
Italy	233 019	355	33 415	75	Community transmission	0
Germany	181 815	333	8 511	11	Community transmission	0
Turkey	163 942	839	4 540	25	Community transmission	0
France	148 524	88	28 746	29	Community transmission	0
Belgium	58 381	195	9 467	14	Community transmission	0
Netherlands	46 442	185	5 956	5	Community transmission	0

Belarus	42 556	898	235	6	Community transmission	0
Sweden	37 542	429	4 395	0	Community transmission	0
Portugal	32 500	297	1 410	14	Community transmission	0
Switzerland	30 779	17	1 656	0	Community transmission	0
Ireland	24 990	61	1 652	1	Community transmission	0
Ukraine	24 012	340	718	10	Community transmission	0
Poland	23 786	215	1 064	3	Community transmission	0
Romania	19 257	124	1 262	9	Community transmission	0
Israel	17 071	59	285	1	Pending	0
Austria	16 642	4	668	0	Community transmission	0
Denmark	11 669	36	574	3	Community transmission	0
Serbia	11 412	31	243	1	Pending	0
Kazakhstan	11308	450	41	3	Clusters of cases	0
Armenia	9 492	210	139	8	Community transmission	0
Czechia	9 273	43	320	1	Clusters of cases	0
Norway	8 411	0	236	0	Clusters of cases	2
Republic of Moldova	8 251	153	295	1	Community transmission	0
Finland	6 859	33	320	4	Pending	0
Azerbaijan	5 494	248	63	2	Clusters of cases	0
Luxembourg	4 018	2	110	0	Clusters of cases	0
Tajikistan	3 930	123	47	0	Pending	0
Hungary	3 876	9	526	2	Community transmission	0
Uzbekistan	3 662	108	15	1	Clusters of cases	0
Greece	2 917	2	175	0	Clusters of cases	0

Bulgaria	2 513	0	140	0	Clusters of cases	1
Bosnia and Herzegovina	2 509	16	152	0	Community transmission	0
Croatia	2 246	0	103	0	Community transmission	1
North Macedonia	2 226	62	133	2	Clusters of cases	0
Estonia	1 869	4	68	1	Pending	0
Kyrgyzstan	1 817	69	16	0	Clusters of cases	0
Iceland	1 806	0	10	0	Community transmission	1
Lithuania	1 675	5	70	0	Community transmission	0
Slovakia	1 522	1	28	0	Clusters of cases	0
Slovenia	1 473	0	108	0	Clusters of cases	3
Albania	1 143	7	33	0	Clusters of cases	0
Latvia	1 066	1	24	0	Clusters of cases	0
Cyprus	944	1	17	0	Clusters of cases	0
Georgia	794	11	12	0	Community transmission	0
Andorra	764	0	51	0	Community transmission	3
San Marino	687	0	42	0	Community transmission	3
Malta	616	0	7	0	Sporadic cases	3
Montenegro	324	0	9	0	Clusters of cases	26
Monaco	98	0	1	0	Sporadic cases	8
Liechtenstein	83	0	1	0	Pending	36
Holy See	12	0	0	0	Sporadic cases	25
Territories ⁱⁱ						
Kosovo ^[1]	1 064	0	30	0	Community transmission	1
Isle of Man	336	0	24	0	Pending	10

Jersey	308	0	29	0	Community transmission	3
Guernsey	252	0	13	0	Community transmission	29
Faroe Islands	187	0	0	0	Pending	38
Gibraltar	169	8	0	0	Clusters of cases	0
Greenland	13	0	0	0	Pending	3
South-East Asia						
India	190 535	8 392	5 394	230	Clusters of cases	0
Bangladesh	47 153	2 545	650	40	Community transmission	0
Indonesia	26 473	700	1 613	40	Community transmission	0
Thailand	3 082	1	57	0	Clusters of cases	0
Maldives	1 773	101	5	0	Clusters of cases	0
Sri Lanka	1 633	13	10	0	Clusters of cases	0
Nepal	1 572	171	8	2	Sporadic cases	0
Myanmar	224	0	6	0	Clusters of cases	1
Bhutan	43	10	0	0	Sporadic cases	0
Timor-Leste	24	0	0	0	Clusters of cases	38
Western Pacific						
China	84 588	18	4 645	0	Clusters of cases	0
Singapore	34 884	518	23	0	Clusters of cases	0
Philippines	18 086	862	957	7	Community transmission	0
Japan	16 884	33	892	1	Clusters of cases	0
Republic of Korea	11 503	35	271	1	Clusters of cases	0
Malaysia	7 819	57	115	0	Clusters of cases	0

Australia	7 195	10	103	0	Clusters of cases	0
New Zealand	1 154	0	22	0	Clusters of cases	10
Viet Nam	328	0	0	0	Clusters of cases	1
Mongolia	179	0	0	0	Sporadic cases	2
Brunei Darussalam	141	0	2	0	Clusters of cases	24
Cambodia	125	0	0	0	Sporadic cases	2
Lao People's Democratic Republic	19	0	0	0	Sporadic cases	49
Fiji	18	0	0	0	Sporadic cases	41
Papua New Guinea	8	0	0	0	Sporadic cases	39
Territories ⁱⁱ						
Guam	166	0	5	0	Clusters of cases	1
French Polynesia	60	0	0	0	Sporadic cases	26
Northern Mariana Islands (Commonwealth of the)	22	0	2	0	Pending	10
New Caledonia	19	0	0	0	Sporadic cases	3
Other*	741	0	13	0	Not applicable	-

****** See [Annex 1](#) for data, table and figure notes.

Technical guidance and other resources

- To view all technical guidance documents regarding COVID-19, please go to [this webpage](#).
- Updates from WHO regional offices
 - [WHO AFRO](#)
 - [WHO PAHO](#)
 - [WHO EMRO](#)
 - [WHO SEARO](#)
 - [WHO EURO](#)
 - [WHO WPRO](#)
- [Research and Development](#)
- [Online courses on COVID-19](#) and in [additional national languages](#)
- [The Strategic Preparedness and Response Plan](#) (SPRP) outlining the support the international community can provide to all countries to prepare and respond to the virus
- [WHO Health Emergency dashboard](#)
- [Weekly COVID-19 Operations Updates](#)

Recommendations and advice for the public

- [Protect yourself](#)
- [Questions and answers](#)
- [Travel advice](#)
- [EPI-WIN](#): tailored information for individuals, organizations and communities

Case definitions

WHO periodically updates the [Global Surveillance for human infection with coronavirus disease \(COVID-19\)](#) document which includes surveillance definitions.

Definition of COVID-19 death

COVID-19 death is defined for surveillance purposes as a death resulting from a clinically compatible illness in a probable or confirmed COVID-19 case, unless there is a clear alternative cause of death that cannot be related to COVID-19 disease (e.g. trauma). There should be no period of complete recovery between the illness and death.

Further guidance for certification and classification (coding) of COVID-19 as cause of death is available [here](#).

Annex 1: Data, table and figure notes

Caution must be taken when interpreting all data presented. Differences are to be expected between information products published by WHO, national public health authorities, and other sources using different inclusion criteria and different data cut-off times. While steps are taken to ensure accuracy and reliability, all data are subject to continuous verification and change. Case detection, definitions, testing strategies, reporting practice, and lag times differ between countries/territories/areas. These factors, amongst others, influence the counts presented, with variable underestimation of true case and death counts, and variable delays to reflecting these data at global level.

The designations employed, and the presentation of these materials do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. Countries, territories and areas are arranged under the administering WHO region.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

[1] All references to Kosovo should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). In the map, number of cases of Serbia and Kosovo (UNSCR 1244, 1999) have been aggregated for visualization purposes.

Counts reflect laboratory-confirmed cases and deaths, based on [WHO case definitions](#), unless stated otherwise (see Country, territory, or area-specific updates and errata), and include both domestic and repatriated cases.

Other*: includes cases reported from international conveyances.

Due to the recent trend of countries conducting data reconciliation exercises which remove large numbers of cases or deaths from their total counts, WHO will now display such data as negative numbers in the "new cases" / "new deaths" columns as appropriate. This will aid readers in identifying when such adjustments occur. When additional details become available that allow the subtractions to be suitably apportioned to previous days, graphics will be updated accordingly. Prior situation reports will not be edited; see covid19.who.int for the most up-to-date data.

Additional table notes

ⁱ Transmission classification is based on a process of country/territory/area self-reporting. Classifications are reviewed on a weekly basis, may be revised as new information becomes available, and are based on the highest category reported. Differing degrees of transmission may be present within countries/territories/areas. Categories:

- No cases: with no confirmed cases
- Sporadic cases: with one or more cases, imported or locally detected.
- Clusters of cases: experiencing cases, clustered in time, geographic location and/or by common exposures.
- Community transmission: experiencing larger outbreaks of local transmission defined through an assessment of factors including, but not limited to: large numbers of cases not linkable to transmission chains; large numbers of cases from sentinel lab surveillance; and/or multiple unrelated clusters in several areas of the country/territory/area.
- Pending: transmission classification has not been reported to WHO.

ii “Territories” include territories, areas, overseas dependencies and other jurisdictions of similar status.

Country, territory, or area-specific updates and errata

No new updates/errata. For previous information, see the [log of major changes and errata](#).